{"id":3560,"date":"2018-11-09T11:53:04","date_gmt":"2018-11-09T06:23:04","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3560"},"modified":"2024-09-18T15:08:56","modified_gmt":"2024-09-18T09:38:56","slug":"triple-negative-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer","title":{"rendered":"Triple Negative Breast Cancer"},"content":{"rendered":"<p style=\"text-align: justify;\">What is <strong>Triple Negative Breast Cancer<\/strong>?<\/p>\n<p style=\"text-align: justify;\"><strong>Triple Negative Breast Cancer (TNBC)<\/strong> is defined as a heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, and there is a lack of overexpression of HER2, as assessed by <strong>immunohistochemistry<\/strong> (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique.<\/p>\n<p style=\"text-align: justify;\">There has been plethora of cases that showed <strong>China<\/strong> accounted for <strong>43%<\/strong> of the total diagnosed incident cases, followed by the <strong>US <\/strong>for <strong>24%<\/strong> of these cases, out of all TNBC cases in G8 countries in 2016. Amongst the EU-5 countries, <strong>Germany<\/strong> had the highest diagnosed incidence (<strong>32%<\/strong>) of TNBC in the year <strong>2016<\/strong> while <strong>Spain<\/strong> was accountable for the least number of TNBC incident cases.<\/p>\n<p style=\"text-align: justify;\">Considering market outlook, the therapeutic market for TNBC in G8 Countries is expected to <strong>increase<\/strong> at a <strong>CAGR<\/strong> of <strong>18.9%<\/strong> by <strong>2027<\/strong>, for the study period 2016-2027. Currently, the therapeutic market size of <strong>metastic TNBC<\/strong> (mTNBC) in the United States is mainly held by the systemic chemotherapies (either alone or in combination), such as <strong>Paclitaxel (Abraxane), Erbulin (Halaven), Carboplatin, Cisplatin, and Docetaxel<\/strong>, among others. These chemotherapies are being used off-label, both in first line as well as in second line treatment settings of TNBC patients, with variation in the dosing frequency and drug-combinations. The United States accounts for the largest market size of TNBC, in comparison to the other G8 countries i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), Japan, and China. The country held a <strong>USD 84 Million<\/strong> market share in <strong>2016<\/strong> and this share is expected to increase by 2027.<\/p>\n<p style=\"text-align: justify;\">The TNBC treatment- <strong>Lynparza<\/strong> (Olaparib; AstraZeneca), a <strong>poly ADP ribose polymerase (PARP)<\/strong> inhibitor, became the first non-chemotherapy treatment for patients with an inherited BRCA mutation (also known as gBRCA or germline BRCA) and HER2-negative metastatic breast cancer, to receive the <strong>U.S. Food and Drugs Administration<\/strong> (<strong>USFDA<\/strong>) approval. Although the drug is not specifically approved for TNBC patients, it still provides a novel treatment option for mTNBC patients with BRCA mutation. Upcoming therapies, such as <strong>Sacituzumab Govitecan<\/strong> (<strong>Immunomedics<\/strong>) in 2019, <strong>Pembrolizumab<\/strong> (<strong>Roche<\/strong>), <strong>Niraparib<\/strong> (<strong>Tesaro<\/strong>) and <strong>Rucuparib<\/strong> (<strong>Clovis Oncology<\/strong>) have the potential to create a significant <strong>positive<\/strong> shift in the TNBC market size during the study period (2016-2027). The launch of Sacituzumab Govitecan in US and EU will have a significant impact on the overall market.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>What is Triple Negative Breast Cancer? Triple Negative Breast Cancer (TNBC) is defined as a heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3565,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2126,137,2125,2122,2124,2120,1632,2121],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-3560","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-anthrax-toxin-receptor-1-antxr1","tag-cancer","tag-cryogenic-electron-microscopy","tag-seneca-valley-virus","tag-university-of-otago","tag-virotherapy","tag-virus","tag-world-health-organization-who","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Breast Cancer Market | Delveinsight<\/title>\n<meta name=\"description\" content=\"Delveinsight expressed the Triple Negative Breast Cancer as a heterogeneous breast cancer phenotype where the estrogen &amp; progesterone receptor are negative, and it is a lack of overexpression of HER2. There has been plethora of cases that presented China accounted for 43% of the total analyzed incident cases. The TNBC Treatment-Lynparza, a poly ADP ribose polymerase,food and Drugs Administration approval.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Breast Cancer Market | Delveinsight\" \/>\n<meta property=\"og:description\" content=\"Delveinsight expressed the Triple Negative Breast Cancer as a heterogeneous breast cancer phenotype where the estrogen &amp; progesterone receptor are negative, and it is a lack of overexpression of HER2. There has been plethora of cases that presented China accounted for 43% of the total analyzed incident cases. The TNBC Treatment-Lynparza, a poly ADP ribose polymerase,food and Drugs Administration approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-09T06:23:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T09:38:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09172654\/Capture.png\" \/>\n\t<meta property=\"og:image:width\" content=\"673\" \/>\n\t<meta property=\"og:image:height\" content=\"504\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Breast Cancer Market | Delveinsight","description":"Delveinsight expressed the Triple Negative Breast Cancer as a heterogeneous breast cancer phenotype where the estrogen & progesterone receptor are negative, and it is a lack of overexpression of HER2. There has been plethora of cases that presented China accounted for 43% of the total analyzed incident cases. The TNBC Treatment-Lynparza, a poly ADP ribose polymerase,food and Drugs Administration approval.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer","og_locale":"en_US","og_type":"article","og_title":"Breast Cancer Market | Delveinsight","og_description":"Delveinsight expressed the Triple Negative Breast Cancer as a heterogeneous breast cancer phenotype where the estrogen & progesterone receptor are negative, and it is a lack of overexpression of HER2. There has been plethora of cases that presented China accounted for 43% of the total analyzed incident cases. The TNBC Treatment-Lynparza, a poly ADP ribose polymerase,food and Drugs Administration approval.","og_url":"https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-11-09T06:23:04+00:00","article_modified_time":"2024-09-18T09:38:56+00:00","og_image":[{"width":673,"height":504,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09172654\/Capture.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer","url":"https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer","name":"Breast Cancer Market | Delveinsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09172654\/Capture.png","datePublished":"2018-11-09T06:23:04+00:00","dateModified":"2024-09-18T09:38:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Delveinsight expressed the Triple Negative Breast Cancer as a heterogeneous breast cancer phenotype where the estrogen & progesterone receptor are negative, and it is a lack of overexpression of HER2. There has been plethora of cases that presented China accounted for 43% of the total analyzed incident cases. The TNBC Treatment-Lynparza, a poly ADP ribose polymerase,food and Drugs Administration approval.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/triple-negative-breast-cancer#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09172654\/Capture.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09172654\/Capture.png","width":673,"height":504,"caption":"Triple Negative Breast Cancer"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09172654\/Capture-300x225.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">anthrax toxin receptor 1 (ANTXR1)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cryogenic-electron microscopy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Seneca Valley Virus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">University of Otago<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Virotherapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">virus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">World Health Organization (WHO)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">anthrax toxin receptor 1 (ANTXR1)<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">cryogenic-electron microscopy<\/span>","<span class=\"advgb-post-tax-term\">Seneca Valley Virus<\/span>","<span class=\"advgb-post-tax-term\">University of Otago<\/span>","<span class=\"advgb-post-tax-term\">Virotherapy<\/span>","<span class=\"advgb-post-tax-term\">virus<\/span>","<span class=\"advgb-post-tax-term\">World Health Organization (WHO)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Nov 9, 2018","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Nov 9, 2018 11:53 am","modified":"Updated on Sep 18, 2024 3:08 pm"},"featured_img_caption":"Triple Negative Breast Cancer","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3560"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3560\/revisions"}],"predecessor-version":[{"id":29620,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3560\/revisions\/29620"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3565"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3560"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3560"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}